Is This Centrally Positioned AI Healthcare Co. Set to Transform the Industry?
Source: Clive Maund  (12/20/24)
Technical Analyst Clive Maund explains why he thinks Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) offers potential upside to investors. More >

Medical Equipment Co. Shows Strong Profit Margin
Source: Dr. Douglas Loe  (12/20/24)
Despite this, the Buy-rated company remains undervalued by the markets due to ongoing business risk, noted a Leede Financial Inc. report. More >

Biopharma Using AI to Find Promising Cancer Drug Candidates
Source: Streetwise Reports  (12/19/24)
Biopharmaceutical company Rakovina Therapeutics Inc. (RKV:TSX.V) summarizes its achievements for 2024 and outlines its goals for the coming year. Find out how the company is using AI to accelerate drug development. More >

New Data Supports BLA Package
Source: Andrew Fein  (12/17/24)
Annexon Inc. (ANNX:NASDAQ) recently released real-world evidence data comparing it's ANX005 to standard treatments for Guillain-Barr Syndrome (GBS), according to an H.C. Wainwright & Co. research note. More >

New Quebec Law Affecting Healthcare Co.'s Bottom Line
Source: Douglas Lowe  (12/16/24)
Quebec-based staffing operator Premier Health of America Inc. (PHA:TSX.V) reported soft financial data for the fourth quarter of 2024 as the province's Bill 10 act limiting the use of per diem operations. Find out why this analyst thinks things will improve for the company. More >

Biotech's Parkinson's Drug Could Be Worth US$4B, Analyst Says
Source: Streetwise Reports  (12/10/24)
Clinical-stage biotechnology company Gain Therapeutics Inc.'s (GANX:NASDAQ) drug treating Parkinson's disease could be a "US$4 billion drug," according to one analyst who recently initiated coverage on the Maryland company. More >

California Biopharma Shows Promising Phase 1 Data
Source: Jason Kolbert  (12/9/24)
Artelo Biosciences Inc. (ARTL:NASDAQ) recently reported promising Phase 1 results from its CAReS trial evaluating ART27.13 for cancer-related anorexia, according to a D. Boral Capital research note. More >

FDA Decision on Drug for Bone Marrow Due Early 2025
Source: Dr. Douglas Loe  (12/6/24)
The manufacturer sheds light on the amount and remittance schedule of the cash payment it must remit to its partner if the drug gets approved, noted a Leede Financial Inc. report. More >

Drug Trial Shows Positive Interim Results for ALS Treatment
Source: Streetwise Reports  (12/6/24)
Biopharmaceutical company MediciNova Inc. (MNOV:NASDAQ) announced the release of a positive interim analysis of its treatment of Amyotrophic Lateral Sclerosis (ALS). Find out why one analyst says the drug has "potential" to treat the disease and maybe others. More >

AI Accelerates Breakthroughs in Cancer Drug Discovery
Source: Streetwise Reports  (12/3/24)
Rakovina Therapeutics Inc. (RKV:TSX.V) is advancing cancer drug discovery with its Deep Docking AI platform. Read more about their recent developments and future plans. More >

Intratubal Insemination Device Shown Effective, Safe
Source: Emily Bodnar  (12/3/24)
Pregnancy rates with this "only new innovation for infertility in decades" were "impressive" in a pivotal study in women with male factor infertility, noted an H.C. Wainwright & Co. report. More >

Approval Sought in Japan for New Drug to Lower Cholesterol
Source: Dr. Joseph Pantginis  (12/3/24)
The U.S. biopharma behind the drug is "pushing for accelerated adoption and expansion into additional territories," noted an H.C. Wainwright & Co. report. More >

Regenerative Medicine Co. Adds Saudi Arabia Diabetes Initiative
Source: Streetwise Reports  (12/3/24)
Leading regenerative medicine company Sernova Corp. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces agreement to explore fighting type I diabetes in Saudi Arabia. Read why one analyst believes the company's technology is "advanced." More >

Is This California Biopharma Co. In the Right Place at the Right Time?
Source: Dr. Jonathan Aschoff  (12/3/24)
Roth MKM analyst Dr. Jonathan Aschoff highlighted GT Biopharma Inc.'s (GTBP:NASDAQ) development of unique precision therapeutic agents using camelid-derived nanobodies. More >

Developer of Medical Instruments Attracts Research Coverage
Source: Douglas Loe  (12/2/24)
Both of this Buy-rated company's two business divisions are contributing to topline growth, noted a Leede Financial Inc. report. More >

Two Firms Aim To Create Functional Cure for Type 1 Diabetes
Source: Streetwise Reports  (11/22/24)
Each company is pursuing its own treatment approach to achieve insulin independence, consisting of islet cells (donor or stem cell derived), delivered into the portal vein or housed in a Cell Pouch bio-hybrid organ that is implanted in the body. Learn more about their respective programs. More >

Biotech Initiates Phase III Trial for Heart Disease Drug
Source: Streetwise Reports  (11/20/24)
Clinical-stage life sciences company Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) is setting up a phase III trial for its pericarditis drug, CardioRx, after pilot study sees success. Read why analysts like this biotech stock. More >

Analyst Says Biotech's Data Supports Advancement Into Phase III
Source: Dr. Douglas Loe  (11/19/24)
Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) recently released updated Phase II data from the MAvERIC trial testing CardiolRx in recurrent pericarditis, according to a Leede Financial Inc. research note. More >

Breakthrough Therapy Shows Promising Long-Term Results for Depression
Source: Streetwise Reports  (11/19/24)
Cybin Inc. (CYBN:NYSE American; CYBN:NEO) has announced positive results from its 12-month Phase 2 study of CYB003, a proprietary deuterated psilocin program designed for the adjunctive treatment of major depressive disorder (MDD). Find out about the FDA's designation of this treatment and why the Chief Medical Officer sees this news as "highly encouraging." More >

Transformative Moves in Harm Reduction Expanding Market Reach with New Partnerships and Acquisitions
Source: Streetwise Reports  (11/15/24)
Safe Supply Streaming Co. Ltd (SPLY:CSE; SSPLF:OTCQB; QM4:FSE) recently announced significant developments within its portfolio company, Safety Strips, and a key acquisition. Learn more about how these strategic developments aim to enhance harm reduction efforts and expand market reach.

More >

Prestigious Honors Show How This Defense Company Supports Veterans and Leads in Innovation
Source: Streetwise Reports  (11/14/24)
DroneShield Ltd. (DRO:ASX; DRSHF:OTC), headquartered in Warrenton, Virginia, has been honored with the prestigious 2024 HIRE Vets Medallion Award in recognition of its commitment to hiring and supporting U.S. military veterans. Read the CEO's response to the honor and the company's commitment to veterans. More >

Opportunity Arises for Co. With Cell Pouch
Source: Dr. Douglas Loe  (11/12/24)
This medical device owner could team up with a biotech firm that just prioritized its diabetes program, noted a Leede Financial Inc. report. More >

Rising Revenue and Strategic Pipeline Advances Propel Biotech Growth Trajectory
Source: Streetwise Reports  (11/8/24)
Vertex Pharmaceuticals Inc. (VRTX:NASDAQ) has reported a robust financial performance for the third quarter of 2024. Read the details on this announcement and some of the primary drivers behind the rise. More >

New Blood Cancer Treatment Shows Continued Response
Source: Dr. David Nierengarten  (11/7/24)
The biotech behind this cell therapy has numerous near-term catalysts related to its pipeline, noted a Wedbush report. More >

Regenerative Med Co. Granted Second Tissue License
Source: Dr. Jonathan Aschoff  (11/7/24)
With these expanded capabilities, the biotech may increase revenue generation and continue its clinical trial, noted a Roth MKM report. More >